Drug Profile
Research programme: moraxella catarrhalis vaccine - BioPort/GlaxoSmithKline
Latest Information Update: 18 Jan 2008
Price :
$50
*
At a glance
- Originator Emergent BioDefense Operations Lansing
- Class Bacterial vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Otitis media
Most Recent Events
- 17 Jun 2003 No development reported - Preclinical for Otitis media in USA (unspecified route)
- 16 Jun 2003 The assets of Antex Biologics and Antex Pharma have been acquired by BioPort Corporation
- 21 May 2001 GlaxoSmithKline has licensed the vaccine